



STATE OF TENNESSEE
BUREAU OF TENNCARE
DEPARTMENT OF FINANCE AND ADMINISTRATION
729 CHURCH STREET
NASHVILLE, TENNESSEE 37247-6501

Memorandum

DATE: October 24, 2003

TO: All TennCare Pharmacy Advisory Committee Members

FROM: David O. Hollis, M.D.

RE: Final Phase II Drug List

Attached you will find the final version of the Phase II drug list we intend to post on the TennCare website and distribute to TennCare providers. As you know, the Phase II drugs will be implemented on November 15, 2003.

Following the last committee meeting, TennCare and ACS continued to evaluate the recommendations of the committee. The committee suggestions which varied from the initial recommendations of ACS included:

- the addition of Detrol LA® and Oxytrol® to the urinary tract antispasmodic category
- the addition of Avandia® and Avandamet® to the hypoglycemics, insulin-response enhancers category and
- the addition of Amaryl® to the hypoglycemics, sulfonylureas and combinations category

TennCare agrees with these recommendations of the committee and those additions will be made to the TennCare PDL.

After careful deliberation, TennCare has made some other changes to the PDL, about which I would like to advise the committee. There currently is no generic form of fenofibrate available on the market and therefore we are adding TriCor® to the PDL. TennCare will receive supplemental rebates/savings from this product that are expected to exceed three hundred thousand dollars per year. TennCare has also decided, due to some stability issues, to add Novolog and the Novolog® mixes to the PDL (including the pen and inolet systems).

As always, we appreciate the hard work of the committee and the sacrifice you make both personally and professional to serve on this important committee. Please contact me if you have any questions, comments or if you need any additional information.

As you know, the next committee meeting is scheduled for November 12, 2003. I look forward to seeing you at the meeting. Thank you.